Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M

Kiniksa Pharmaceuticals International, plc

2026-Q1 EPS reported $0.27 revenue$214,266,000

ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.
2026 ARCALYST net product revenue guidance raised to $930-$945 million from prior $900-$920 million.
Cash and short-term investments $468.1 million, no debt; net income $22.6 million in Q1 2026.
KPL-387 Phase 2 data in recurrent pericarditis expected in 2H 2026; Phase 3 trial by year-end.
Over 4,550 prescribers for ARCALYST in recurrent pericarditis; average therapy duration approaching 3 years.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kiniksa Pharmaceuticals International, plc reported the quarter ended March 31, 2026 results: revenue $214.3 million, net income $22.6 million. Guidance raised.

Period: the quarter ended March 31, 2026
Revenue: $214.3 million
Net income: $22.6 million
Guidance: raised
Result: reported results

Exact text from the filing

--- Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001730430-26-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.